[Role of PD-1/PD-L1 in microenvironment of breast cancer]

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Programmed cell death protein 1 (PD-1) acts as an immune checkpoint.
• Its ligand, PD-L1, mediates immune suppression.
• The PD-1/PD-L1 pathway is a critical target in immuno-oncology.

Purpose of the Study:

• To review the discovery and signaling pathways of PD-1 and PD-L1.
• To explore the application of PD-1/PD-L1 inhibitors in breast cancer.
• To summarize recent research on PD-1/PD-L1 in the breast cancer microenvironment.

Main Methods:

• Literature review of PD-1 and PD-L1.
• Analysis of signaling pathways.
• Summary of inhibitor types and clinical applications.
• Review of preclinical and clinical studies in breast cancer.

Main Results:

• PD-1/PD-L1 pathway negatively regulates immune responses.
• PD-1/PD-L1 inhibitors show promise in various cancers, including breast cancer.
• Understanding the tumor microenvironment is crucial for effective inhibitor therapy.

Conclusions:

• PD-1/PD-L1 inhibitors represent a significant advancement in cancer treatment.
• Further research into the PD-1/PD-L1 mechanism in breast cancer is needed.
• Optimizing PD-1/PD-L1 inhibitor strategies can enhance therapeutic efficacy.